CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 671614-671804 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T34864","span":{"begin":0,"end":190},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Long-term administration of TAA-HFA 440 μg exhibited a good safety and tolerability profile, while providing moderate-to-complete symptom relief in more than 80% of patients treated for PAR."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T375","span":{"begin":0,"end":190},"obj":"Sentence"}],"text":"Long-term administration of TAA-HFA 440 μg exhibited a good safety and tolerability profile, while providing moderate-to-complete symptom relief in more than 80% of patients treated for PAR."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6218","span":{"begin":32,"end":35},"obj":"Disease"}],"attributes":[{"id":"A6218","pred":"mondo_id","subj":"T6218","obj":"http://purl.obolibrary.org/obo/MONDO_0007710"}],"text":"Long-term administration of TAA-HFA 440 μg exhibited a good safety and tolerability profile, while providing moderate-to-complete symptom relief in more than 80% of patients treated for PAR."}